Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(3), 298-305 | ISSN:2251-6727

# Sickle Cell Disease: Pathophysiology, Global Burden, and Current Treatment Strategies

**[1]Ashvini Ingle Ghirke, [2]Dr. Sapna Singh**

[1]Mansarovar global University,Bhopal, Dept. Microbiology.

[2]Dept of Microbiology, Mansarovar global University,Bhopal

***(Received: 16 March 2025 Revised: 20 April 2025 Accepted: 01 May2025)***

**KEYWORDS**

Sickle Cell Disease (SCD), Hemoglobin S, Vaso-occlusive Crisis, Hemolytic Anemia, Global Health Burden, Pathophysiology, Hydroxyurea Therapy, Blood Transfusion.

**ABSTRACT:**

The beta-globin gene mutation in sickle cell disease brings about the development of anomalous hemoglobin S (HbS) which leads to the creation of abnormal blood cells known as sickle cells. HbS polymerizes under low-oxygen levels which causes deformations of red blood cells into The sickle shape. The process of sickled cells blocking regular blood circulation leads to vaso-occlusive crises as well as chronic hemolytic anemia and organ damage and produces a very poor life quality. The different complications of the disease such as acute chest syndrome and strokes and splenic system failure and chronic pain account for high death rates and increased illness burden. SCD exists throughout the world but it remains most common in areas formerly burdened by malaria including Sub-Saharan Africa and India together with the Middle East and the Mediterranean. The current year brings about 300,000 new SCD births across the world while low-resource nations suffer the most from inadequate disease management systems because of limited healthcare capabilities. Medical scientific progress has led to raised survival possibilities alongside improved quality of life outcomes for SCD patients located in high-income nations. Multiple disease management approaches including newborn screening, prophylactic antibiotics, vaccinations and hydroxyurea therapy and blood transfusions and bone marrow transplantation with gene therapy have proven influential in managing SCD. The field of gene therapy presents itself as a promising solution which now shows promise to patients as a potential cure. Multiple knowledge gaps persist after the introduction of these new strategies. The absence of early diagnosis together with insufficient treatment options and insufficient care programs which operate in low- and middle-income countries leads to persistently high childhood death rates resulting in reduced life spans for children. The affected populations face increased challenges because of economic limitations together with social discrimination and insufficient public health efforts. The existing therapeutic approaches for treating this condition aim primarily to control symptoms while failing to deliver a cure for the disease. Patients need regular monitoring when taking hydroxyurea whereas blood transfusions result in two major risks of iron overload and alloimmunization. Because of high costs and donor requirements bone marrow transplant stands as a curative option which limits its accessibility. Most patients lack access to gene therapeutic treatments because they are still experimental procedures and because monetary barriers exist. This research examines SCD molecular pathophysiology while assessing disease prevalence across different regions then reviews therapeutic approaches and argues for equal healthcare distribution. The necessary link between medical innovation and availability must be established to enhance health outcomes for sickle cell disease patients worldwide.

**Introduction**:

The genetic disorder sickle cell disease produces the abnormal HbS protein due to a beta-globin gene mutation which leads to the development of this chronic hereditary blood disorder (Steinberg et al., 2009). The body reacts to reduced oxygen amounts by allowing

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(3), 298-305 | ISSN:2251-6727

HbS molecules to combine into polymers which then transform healthy red blood cells into rigid sickle-shaped cells. Hemoglobin S deformed cells maintain an abnormal rigid shape because of their lost flexibility which then causes blood vessel blockages that reduces tissue and organ blood supply. Conditions arising from sickle cell disease bring about vaso-occlusive crises along with chronic hemolytic anemia and progressive organ damage which severely impairment both the health status and daily lives of affected patients (Rees et al., 2022). Annually approximately 300,000 infants worldwide receive a SCD diagnosis with most cases occurring throughout Sub-Saharan Africa and the Middle East as well as India (*Sickle Cell Disease in Sub-Saharan Africa - PMC*, n.d.). Sub-Saharan Africa reports SCD as a major death cause of childhood mortality because many infected children die from serious infections while lacking proper healthcare access (Williams, 2016). The rate of SCD-related illness in India affects tribal populations as well as marginalized communities since these groups lack proper access to adequate healthcare (Colah et al., 2015). Several events unfold in series after the sickling process occurs to red blood cells during the pathophysiology of SCD. No blood flow due to vaso-occlusion results in tissue infarction along with chronic anemia and oxidative stress because of ongoing hemolysis according to Hebbel . A chronic inflammatory condition initiated by the disease worsens vascular injuries and end-organ destruction. The disease processes give rise to multiple acute and chronic medical conditions including acute chest syndrome together with stroke coupled with renal impairment and leg ulcer development (Colah et al., 2015). The medical breakthrough using hydroxyurea to raise fetal hemoglobin content along with scheduled blood transfusion and developing gene treatment options has not eliminated SCD which continues to pose significant health challenges to populations in low and middle-income nations (Egesa et al., 2022). High treatment expenses together with insufficient medical facilities and social economic differences create ongoing healthcare disparities between wealthy and understaffed healthcare sectors. The genetic and hematological disorder SCD demands complete strategies involving treatment of medical aspects together with psychological needs and societal factors because of its role as both an economic issue and public health threat. The expansion of research for innovative medical approaches along with enhanced global healthcare infrastructure is crucial for lowering the impact of this life-threatening condition.

**Pathophysiology of Sickle Cell Disease (SCD)**

The single genetic defect in β-globin gene at chromosome 11 causes sickle cell disease (SCD). This mutation produces HbS by replacing valine into the sixth position of the β-globin chain at glutamic acid ((Booth et al., 2010). The single nucleotide change in SCD disrupts red blood cells (RBCs) both structurally and behaviorally. Red blood cells maintain their deformability and biconcave shape under normal oxygenated conditions because the solubility of hemoglobin molecules remains preserved. This allows smooth blood vessel transit. The red cell transformation into rigid fibers occurs due to polymerization of HbS molecules when people with SCD experience deoxygenation. Popularization of the proteins inside cells produces the distinctive crescent or sickle cell morphology (Rees et al., 2010). The lifespan of about 120 days for normal red blood cells stands in contrast to sickled cells which get destroyed through premature destruction (hemolysis) between 10–20 days thus causing chronic anemia. Red blood cell sickling functions as a trigger for several destructive disease-related processes. The rigidity of sickle cells leads to a decreased deformability and increased adherence to the vascular endothelium which causes blockages in small blood vessels through vaso-occlusion. Acute severe pain vaso-occlusive crises appear when vaso-occlusion results in decreased blood supply to the tissues that later develops into ischemia. Multiple episodes of vaso-occlusion lead to permanent damage of various tissues and organs with special consequences for lungs and kidneys and spleen and brain (Elendu et al., 2023). Blood flow obstruction remains one main condition of SCD along with persistent inflammatory responses from within the body. The ongoing process of hemolysis causes plasma free hemoglobin to soak up nitric oxide molecules that maintain vascular health. The condition worsens vascular function while triggering inflammatory responses and increases the dangers of pulmonary hypertension and leg ulcers and stroke development(Lai et al., 2014). The decomposition process of sickled cells along with free radical-induced

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(3), 298-305 | ISSN:2251-6727

oxidative stress results in more damaged endothelial cells which both increase inflammation and promote clot formation. SCD patients show increased production of inflammatory cytokines IL-6 and TNF-α which cause prolonged vascular injury together with systemic health complications . A single genetic mutation at its origin creates complications through the disease pathophysiology as it advances into polymerization then triggers hemolysis before establishing vaso-occlusion and chronic inflammation and leading to multi-organ dysfunction. The research of interlinked disease mechanisms enables healthcare providers to establish treatment methods that control disease progression from its root causes.

**Global Prevalence and Burden of Sickle Cell Disease (SCD)**

The global health problem of Sickle cell disease primarily affects destinations that once endured malarial infections. The sickle cell trait protects heterozygous individuals from developing severe malaria thus enabling the survival of sickle genes within patient populations of Sub-Saharan Africa the Middle East India and parts of the Mediterranean (Oron et al., 2020a). The worldwide birth of SCD patients occurs yearly to the amount of 300,000 cases while low- and middle-income countries have the highest number of births with SCD according to (Inusa et al., 2019)). Sub-Saharan Africa possesses the largest global SCD patient population since it generates more than 75% of annually reported new disease births . Each year 150,000 Nigerian infants suffer from SCD creating the most significant sickle cell disease population globally . Some areas in the Sub-Saharan Africa demonstrate sickle cell gene (HbAS) carrier rates exceeding 20% to 30% of the population. Despite the protective benefit against malaria for carriers, individuals with sickle cell disease (HbSS) face severe health outcomes. Many African nations face a mortality rate of 50%–90% for infants born with SCD because they have no newborn screening programs and limited medical care is available together with high infectious rates (Oron et al., 2020b). The medical condition affects physical health gravely while simultaneously creating heavy financial and social challenges for families and hospital networks.

The sickle cell disease primarily affects tribal along with sociodemographically disadvantaged communities across India. The population in India incorporates about 20 million sickle cell trait carriers and SCD affects 50,000 children born each year according to Jain et al. . The highest number of sickle cell anemia cases exists within the states of Gujarat, Maharashtra, Madhya Pradesh and Chhattisgarh while carrier frequencies span from 10% to 30% across these states. The inadequate healthcare facilities found in tribal areas cause SCD to lead to excessive child deaths coupled with long-term disabilities and economic problems. Even though there is broader awareness and government programs in place challenges persist for large-scale newborn testing together with prompt intervention services and total patient care delivery . SDC presents itself as an illness across the Middle Eastern countries together with Caribbean and Mediterranean nations yet the population prevalence levels remain lower than in Africa and India. Migration has spread the disease globally which resulted in SCD cases increasing in European and North American regions where immigrant communities reside (CDC, 2025). People who have SCD benefit from improved survival rates and better quality of life in developed nations because of enhanced medical treatments that help with early detection and prevention along with expert medical services. Still some portions of healthcare facilities continue to treat disadvantaged racial groups and low-income communities unfairly.

SCD keeps its position as a substantial worldwide health problem throughout areas where access to healthcare remains restricted. The condition leads to both high death rates together with high illness rates and generates distressing economic and social problems. Approval of advances in care and fair access must unite to decrease the worldwide SCD burden.

**Current Treatments for Sickle Cell Disease (SCD)**

The management of sickle cell disease (SCD) has significantly advanced over recent decades, yet many therapies focus primarily on reducing complications rather than providing a definitive cure. The mainstays of current treatment include pharmacological interventions, blood transfusions, and emerging curative strategies such as bone marrow transplantation and gene therapy.

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(3), 298-305 | ISSN:2251-6727

**1. Hydroxyurea Therapy**

Hydroxyurea is the first pharmacological agent approved for the treatment of SCD and remains a cornerstone of care. It acts by stimulating the production of fetal hemoglobin (HbF), which inhibits the polymerization of sickle hemoglobin (HbS) inside red blood cells. This reduces the sickling of cells, lowers blood viscosity, and decreases the frequency and severity of vaso-occlusive crises . Studies have shown that hydroxyurea therapy reduces hospitalization rates, the incidence of acute chest syndrome, and the need for blood transfusions. Despite its effectiveness, hydroxyurea requires regular monitoring of blood counts to detect myelosuppression, and its uptake remains limited in many low-resource settings due to cost, lack of monitoring facilities, and patient hesitancy.

**2. Blood Transfusion Therapy**

Blood transfusions are an essential supportive measure for patients with SCD. They help to increase the proportion of normal red blood cells, improve oxygen delivery, and prevent complications such as stroke, particularly in children at high risk, identified through transcranial Doppler (TCD) screening (Zheng & Chou, 2021). Transfusions can be given acutely during severe anemia or crisis episodes and chronically to prevent recurrent strokes. However, long-term transfusion therapy poses significant risks, including iron overload, alloimmunization, and transfusion-transmitted infections. Iron overload requires the use of chelation therapy, which itself adds a financial and therapeutic burden on patients and healthcare systems.

**3. Bone Marrow (Hematopoietic Stem Cell) Transplantation**

Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-matched sibling donor is currently the only curative treatment available for SCD. Transplantation replaces the patient's defective bone marrow with healthy marrow capable of producing normal red blood cells. Success rates are high, particularly in young patients without significant organ damage. However, this option is limited by the availability of suitable donors, the risk of graft-versus-host disease (GVHD), transplant-related mortality, and high costs. In many developing countries, BMT remains inaccessible due to the lack of specialized centers and financial barriers (Johns Hopkins University School of Medicine et al., 2023).

**4. Gene Therapy**

Gene therapy represents a revolutionary approach to curing SCD. Strategies include introducing a corrected version of the β-globin gene into the patient's hematopoietic stem cells or editing the existing genes to reactivate fetal hemoglobin production. Techniques such as lentiviral gene transfer and CRISPR-Cas9-based genome editing are currently under clinical trials (Esrick et al., 2021). Early results are promising, showing reduction or elimination of vaso-occlusive events and transfusion dependency. However, gene therapy remains highly experimental, extremely costly, and technically demanding, limiting its availability to only a few specialized research centers globally.

**5. Supportive and Preventive Care**

Comprehensive supportive care remains critical in the management of SCD. Newborn screening programs enable early identification and initiation of prophylactic interventions. Penicillin prophylaxis, starting in infancy, significantly reduces the risk of fatal infections such as pneumococcal sepsis. Routine immunizations against pathogens like *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Neisseria meningitidis* are standard. Pain management strategies, psychosocial support, hydration, and education about recognizing early signs of complications are integral components of care. Psychological counseling and chronic disease management programs are increasingly recognized as essential, particularly given the impact of SCD on quality of life, mental health, and social well-being(*Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease | Hematology | JAMA Network Open | JAMA Network*, n.d.) .

**Challenges in Current Treatments**

While these treatment modalities have improved the prognosis and quality of life for many individuals living with SCD, significant challenges persist. Access to treatments like hydroxyurea, blood transfusion services, and advanced therapies remains unequal, particularly in low-income countries. Financial barriers, limited healthcare infrastructure, cultural beliefs, and lack of awareness hinder effective disease management in high-

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(3), 298-305 | ISSN:2251-6727

burden regions like Sub-Saharan Africa and parts of India. Moreover, most current therapies focus on managing symptoms rather than addressing the underlying genetic cause, highlighting the urgent need for broader access to curative interventions like gene therapy and bone marrow transplantation.

**Gaps in Existing Treatment for Sickle Cell Disease**

**Limited Access to Healthcare Services**

The insufficient healthcare facilities in rural regions present major obstacles to many developing nations. The scarcity of healthcare facilities across the land hinders patient access to necessary medical care because there are not enough hospitals or clinics to serve the population.

**The availability of healthcare facilities does not solve the problem because some regions face poor roads coupled with insufficient public transportation.**

**2. Shortage of Trained Medical Personnel**

Low-income countries persistently suffer from a shortage of medical professionals who include both doctors and nursing staff and specialists. A diminished quality of care and impaired ability to effectively treat patients becomes a result.

**Healthcare professionals from poor nations migrate to advanced countries to find better prospects thus intensifying staffing deficiencies.**

**3. Inadequate Medical Equipment and Supplies**

Healthcare facilities serving less-wealthy areas usually cannot afford to purchase recent medical products because of high expenses. The use of outdated medical equipment and tools requires healthcare professionals to rely on ancient diagnostic approaches that negatively affect the quality of delivered care.

Low-income environments face discontinuous essential drugs supply specifically regarding chronic illnesses such as diabetes hypertension and cancer and many other vital medicines. The acquisition of both medications and vaccines needed to treat infectious diseases becomes challenging for healthcare providers in some areas.

**4. High Cost of Treatment**

Treatment options exist but fail to be affordable for the vast majority of people living in poverty-stricken nations. Medical expenses paid personally by patients force them to avoid or delay obtaining necessary medical treatments.

The absence of stable health insurance structures in many developing nations makes people depend on their funds and state medical benefits which frequently fail to provide complete medical cost coverage.

**5. Inadequate Public Health Infrastructure**

Multiple low-income countries experience weak healthcare systems which results in service failures and poor administration performance along with delayed health emergency responses.

Hospital and clinic buildings in low-income countries contain excessive patient numbers therefore both healthcare workers and patients suffer through inadequate medical treatment alongside long service delays.

**6. Limited Access to Advanced Treatment Options**

Specialized medical care remains out of reach because advanced surgical treatments and innovative therapeutic methods and recent pharmaceutical drugs are unavailable in the market. Patients who need advanced treatment for complex medical issues have limited therapeutic possibilities due to this situation.

Long-term management of cardiovascular disease and cancer and diabetes proves difficult because healthcare systems lack adequate long-term care, monitoring resources and treatment facilities.

**7. Lack of Health Education and Awareness**

Health education is insufficient in low-income areas thus people become less aware about prevention methods and how to detect symptoms early and why professional medical help should be sought immediately.

Traditional cultural norms sometimes create conflicts between traditional medical beliefs and present-day medical care therefore people may choose to avoid professional health treatments**.**

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(3), 298-305 | ISSN:2251-6727

**8. Inadequate Disease Prevention and Control Programs**

Public health interventions including immunizations deliver maximum benefits through limited costs but low-income nations face restricted vaccine programs which produces health-threatening reactive diseases.

Medical organizations in various countries lack regular screening programs to detect diseases such as cancer, HIV/AIDS and other conditions. Better treatment results depend on early detection because delayed diagnosis leads patients to reach advanced disease stages at the time of diagnosis**.**

**9. Dependence on Foreign Aid**

The healthcare services in low-income countries depend substantially on international foreign aid. Sustainable self-sufficient healthcare systems are harmed when one depends too heavily on international funding.

**10. Weak Regulation and Oversight**

Some low-income countries neither regulate nor oversee pharmaceutical products which permits the spread of fake or non-standard medical drugs to reach the market.

Public healthcare systems suffer from corruption that triggers financial misconduct which deepens the shortage of essential healthcare resources.

**Future Perspectives**

Healthcare treatment in low-income countries should develop significantly in the future through technological progress as well as new policy regulations. Mobile health solutions combined with telemedicine offer possibilities to decrease health access difficulties particularly in remote locations(Esu et al., 2021). Through the combination of mobile devices with budget-friendly medical equipment together with digital visit services these technologies will assist patients by removing geographical along with economic barriers during healthcare service provision.

The prevention of health problems demands enhanced health education curriculum implementation as a primary strategy to achieve better outcome. Elevating health awareness through community programs focusing on widespread health issues and care solutions helps communities achieve improved medical results and reduces service demands at healthcare facilities (Hoagland & Kipping, 2024). The quality improvement of medical instruction and healthcare personnel retention efforts within the country help mitigate medical professional relocation challenges that commonly impact developing nations (Esu et al., 2021).

International partnerships between public authorities and non-profit groups and private enterprises can develop innovative medical care solutions for healthcare systems lacking adequate resources. The venues created by these partnerships assist in building healthcare systems which function independently from outside support while prioritizing domestic self-reliance ((*U.S.-China Technological "Decoupling": A Strategy and Policy Framework | Carnegie Endowment for International Peace*, n.d.)).

Better resource management along with technological innovation and strategic partnerships will help low-income countries achieve health equity through their healthcare systems. Such investments would boost the living standards of these areas and help meet international healthcare objectives and better worldwide health results.

**Conclusion**

Healthcare treatment in low-income countries faces significant obstacles because systemic limitations restrict patient access to healthcare services. WHO reports (2020) that inadequate healthcare infrastructure along with medical personnel shortages and insufficient medical equipment combined with high treatment costs constitute these challenges. Limited public health education along with scarce access to specialized medical care and advanced healthcare procedures results in a harmful spiral that enlarges health delivery deficiencies. Social and economic challenges that currently strain healthcare systems make existing healthcare gaps in local communities even more substantial thus hindering the success of medical interventions. The improvement of health quality for low-income individuals requires immediate focus because it both ensures personal welfare and establishes global health fairness. North America and India alone are responsible for 354,868 of these mortalities yearly (*Improving Access to Health Care with Emerging Technologies | UNICEF Office of Innovation*, n.d.-a). The importance of improving healthcare facilities along

Journal of Chemical Health Risks

www.jchr.org

JCHR (2025) 15(3), 298-305 | ISSN:2251-6727

with cheaper accessibility to essential treatments remains unsubstitutable (*Improving Access to Health Care with Emerging Technologies | UNICEF Office of Innovation*, n.d.-b). Public health systems need fortification to make all fundamental healthcare services available to everyone in society. Better management practices together with more funding and efficient resource distribution systems along with active community involvement in health promotion constitute vital elements for achieving health improvement (*U.S.-China Technological "Decoupling": A Strategy and Policy Framework | Carnegie Endowment for International Peace*, n.d.).

**References:**

1. Booth, C., Inusa, B., & Obaro, S. K. (2010). Infection in sickle cell disease: A review. *International Journal of Infectious Diseases*, *14*(1), e2–e12. https://doi.org/10.1016/j.ijid.2009.03.010
2. CDC. (2025, January 30). *Laboratory Testing*. Immigrant and Refugee Health. https://www.cdc.gov/immigrant-refugee-health/hcp/domestic-guidance/laboratory-testing.html
3. Colah, R. B., Mukherjee, M. B., Martin, S., & Ghosh, K. (2015). Sickle cell disease in tribal populations in India. *The Indian Journal of Medical Research*, *141*(5), 509–515. https://doi.org/10.4103/0971-5916.159492
4. Egesa, W. I., Nakalema, G., Waibi, W. M., Turyasiima, M., Amuje, E., Kiconco, G., Odoch, S., Kumbakulu, P. K., Abdirashid, S., & Asiimwe, D. (2022). Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond. *International Journal of Pediatrics*, *2022*(1), 3885979. https://doi.org/10.1155/2022/3885979
5. Elendu, C., Amaechi, D. C., Alakwe-Ojimba, C. E., Elendu, T. C., Elendu, R. C., Ayabazu, C. P., Aina, T. O., Aborisade, O., & Adenikinju, J. S. (2023). Understanding Sickle cell disease: Causes, symptoms, and treatment options. *Medicine*, *102*(38), e35237. https://doi.org/10.1097/MD.0000000000035237
6. Esu, E. B., Chibuzor, M., Aquaisua, E., Udoh, E., Sam, O., Okoroafor, S., Ongom, M., Effa, E., Oyo-ita, A., & Meremikwu, M. (2021). Interventions for improving attraction and retention of health workers in rural and underserved areas: A systematic review of systematic reviews. *Journal of Public Health*, *43*(Supplement_1), i54–i66. https://doi.org/10.1093/pubmed/fdaa235
7. *Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease | Hematology | JAMA Network Open | JAMA Network*. (n.d.). Retrieved April 28, 2025, from https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805016
8. Hoagland, A., & Kipping, S. (2024). Challenges in Promoting Health Equity and Reducing Disparities in Access Across New and Established Technologies. *Canadian Journal of Cardiology*, *40*(6), 1154–1167. https://doi.org/10.1016/j.cjca.2024.02.014
9. *Improving Access to Health Care with Emerging Technologies | UNICEF Office of Innovation*. (n.d.-a). Retrieved April 28, 2025, from https://www.unicef.org/innovation/stories/improving-access-health-care-emerging-technologies
10. *Improving Access to Health Care with Emerging Technologies | UNICEF Office of Innovation*. (n.d.-b). Retrieved April 28, 2025, from https://www.unicef.org/innovation/stories/improving-access-health-care-emerging-technologies
11. Inusa, B. P. D., Hsu, L. L., Kohli, N., Patel, A., Ominu-Evbota, K., Anie, K. A., & Atoyebi, W. (2019). Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment. *International Journal of Neonatal Screening*, *5*(2), 20. https://doi.org/10.3390/ijns5020020
12. Johns Hopkins University School of Medicine, Mathews, D., Abernethy, A., Verily, Chaikof, E., Beth Israel Deaconess Medical Center, Alta Charo, R., Alta Charo Consulting, LLC, Daley, G. Q., Harvard Medical School, Enriquez, J., Excel Venture Management, Gottlieb, S., New Enterprise Associates, Kahn, J., Johns Hopkins Berman Institute of Bioethics, Klausner, R. D., Altos Labs,

Tavazoie, S., … National Academy of Medicine. (2023). Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology. *NAM Perspectives*, *11*(15). https://doi.org/10.31478/202211d

13. Lai, Y.-C., Potoka, K. C., Champion, H. C., Mora, A. L., & Gladwin, M. T. (2014). Pulmonary Arterial Hypertension: The Clinical Syndrome. *Circulation Research*, *115*(1), 115–130. https://doi.org/10.1161/CIRCRESAHA.115.301146
14. Oron, A. P., Chao, D. L., Ezeanolue, E. E., Ezenwa, L. N., Piel, F. B., Ojogun, O. T., Uyoga, S., Williams, T. N., & Nnodu, O. E. (2020a). Caring for Africa's sickle cell children: Will we rise to the challenge? *BMC Medicine*, *18*(1), 92. https://doi.org/10.1186/s12916-020-01557-2
15. Oron, A. P., Chao, D. L., Ezeanolue, E. E., Ezenwa, L. N., Piel, F. B., Ojogun, O. T., Uyoga, S., Williams, T. N., & Nnodu, O. E. (2020b). Caring for Africa's sickle cell children: Will we rise to the challenge? *BMC Medicine*, *18*(1), 92. https://doi.org/10.1186/s12916-020-01557-2
16. Rees, D. C., Brousse, V. A. M., & Brewin, J. N. (2022). Determinants of severity in sickle cell disease. *Blood Reviews*, *56*, 100983. https://doi.org/10.1016/j.blre.2022.100983
17. *Sickle Cell Disease in Sub-Saharan Africa—PMC*. (n.d.). Retrieved April 28, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC6858853/
18. *U.S.-China Technological "Decoupling": A Strategy and Policy Framework | Carnegie Endowment for International Peace*. (n.d.). Retrieved April 28, 2025, from https://carnegieendowment.org/research/2022/04/us-china-technological-decoupling-a-strategy-and-policy-framework?lang=en
19. Williams, T. N. (2016). Sickle Cell Disease in Sub-Saharan Africa. *Hematology/Oncology Clinics of North America*, *30*(2), 343–358. https://doi.org/10.1016/j.hoc.2015.11.005
20. Zheng, Y., & Chou, S. T. (2021). Transfusion and Cellular Therapy in Pediatric Sickle Cell Disease. *Clinics in Laboratory Medicine*, *41*(1), 101–119. https://doi.org/10.1016/j.cll.2020.10.007